Register for our free email digests:
Lexicon Pharmaceuticals Inc.
www.lexpharma.com
Latest From Lexicon Pharmaceuticals Inc.
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
With $260m Settlement From Sanofi, Lexicon Looks For New Zynquista Partner
Sanofi terminated its alliance for the SGLT1/2 inhibitor Zynquista, giving Lexicon full control of development in type 1 and type 2 diabetes, but it is seeking a new partner ideally with a European footprint.
Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gastrointestinal
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Lexicon Genetics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Lexicon Pharmaceuticals Inc.
- Senior Management
-
Lonnel Coats, Pres. & CEO
Jeffrey L Wade, EVP, CFO
Praveen Tyle, PhD, EVP, R&D
Pablo Lapuerta, MD, EVP, CMO - Contact Info
-
Lexicon Pharmaceuticals Inc.
Phone: (281) 863-3000
8800 Technology Forest Pl.
The Woodlands, TX 77381-1160
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice